"Vasocrine" formation of tumor cell-lined vascular spaces: Implications for rational design of antiangiogenic therapies

Cancer Research

Volumn 63, Issue 11, 2003, Pages 2812-2819

  Rybak, Susanna M ^a   Sanovich, Elena ^b   Hollingshead, Melinda G ^a   Borgel, Suzanne D ^b   Newton, Dianne L ^b   Melillo, Giovanni ^b   Kong, Dehe ^b   Kaur, Gurmeet ^a   Sausville, Edward A ^a,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; FUMAGILLIN; FUMAGILLOL CHLOROACETYLCARBAMATE; RAZOXANE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG TARGETING; ENDOTHELIUM CELL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MELANOMA CELL; NONHUMAN; PRIORITY JOURNAL; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; CELL HYPOXIA; CYCLOHEXANES; DRUG DESIGN; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; RAZOXANE; SESQUITERPENES; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0037939726     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med., 285: 1182-1186, 1971.
2. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med., 1: 27-31, 1995.
3. Carmeliet, P., and Jain, R. K. Angiogenesis in cancer and other diseases. Nature (Lond.), 407: 249-257, 2000.
4. Maniotis, A. J., Folberg, R., Hess, A., Seftor, E. A., Gardner, L. M. G., Pe'er, J., Trent, J. M., Melzer, P. S., and Hendrix, M. J. C. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am. J. Pathol., 155: 739-752, 1999.
5. Shirakawa, K., Tsuda, H., Heike, Y., Kato, K., Asada, R., Inomata, M., Sasaki, H., Kasumi, H., Yoshimoto, M., Iwanaga, T., Konishi, F., Terada, M., and Wakasugi, H. Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer. Cancer Res., 61: 445-451, 2001.
6. Chang, Y. S., DiTomaso, E., McDonald, D. M., Jones, R., Jain, R. K., and Munn, L. L. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc. Natl. Acad. Sci. USA, 97: 14608-14613, 2000.
7. Timar, J., and Toth, J. Tumor sinuses-vascular channels. Pathol. Oncol. Res., 6: 83-86, 2000.
8. Sood, A. K., Seftor, E. A., Fletcher, M. S., Gardner, L. G., Heidger, P. M., Buller, R. E., Seftor, R. E. B., and Hendrix, M. J. C. Molecular determinants of ovarian cancer plasticity. Am. J. Pathol., 158: 1279-1288, 2001.
9. Willis, R. A. The Spread of Tumors in the Human Body, p. 115. London: Butterworth, 1952.
10. McDonald, D. M., Munn, L., and Jain, R. K. Vasculogenic mimicry: how convincing, how novel and how significant? Am. J. Pathol., 156: 383-388, 2000.
11. Fidler, I. J. Selection of successive tumor lines for metastasis. Nat. New Biol., 242: 148-149, 1973.
12. Hayat, M. A. Principles and Techniques of Electron Microscopy. Vol. 1. New York: Van Nostrand Reinhold Company, 1970.
13. Helmlinger, G., Endo, M., Ferrara, N., Hlatky, L., and Jain, R. K. Formation of endothelial cell networks. Nature (Lond.), 405: 139-141, 2000.
14. Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., and Holash, J. Vascular-specific growth factors and blood vessel formation. Nature (Lond.)., 407: 242-248, 2000.
15. Ingber, D., Fujita, T., Kishimoto, S., Sudo, K., Kanamaru, T., Brem, H., and Folkman, J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature (Lond.), 348: 5555-5557, 1990.
16. Hellmann, K. Overview and historical development of dexrazoxane. Semin. Oncol., 25: 48-54, 1998.
17. Kusaka, M., Sudo, K., Fujita, T., Marui, S., Itoh, F., Ingber, D., and Folkman, J. Potent antiangiogenic action of AGM-1470: comparison to the fumagillin parent. Biochem. Biophys. Res. Commun., 174: 1070-1076, 1991.
18. Le Serve, A. W., and Hellmann, K. Metastases and the normalization of tumor blood vessels by ICRF 159: a new type of drug action. Br. Med. J., 1: 597-601, 1972.
19. Salsbury, A. J., Burrage, K., and Hellmann, K. Inhibition of metastatic spread by ICRF 159: selective deletion of a malignant characteristic. Br. Med. J., 4: 344-346, 1970.
20. Warren, B. A., and Shubik, P. The growth of the blood supply to melanoma transplants in the hamster cheek pouch. Lab. Investig., 15: 464-478, 1966.
21. Albeda, S. M., Oliver, P. D., Romer, L. H., and Buck, C. A. Endo-CAM: a novel endothelial cell-cell adhesion molecule. J. Cell Biol., 110: 1227-1237, 1990.
22. Sood, A. K., Fletcher, M. S., and Hendrix, M. J. C. The embryonic-like properties of aggressive human tumor cells. J. Soc. Gynecol. Investig., 9: 2-9, 2002.
23. Bachelder, R. E., Wendt, M. A., and Mercurio, A. M. Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res., 62: 7203-7206, 2002.
24. Shirakawa, K., Kobayashi, H., Heike, Y., Kawamoto, S., Brechbiew, M. W., Kasumi, F., Iwanaga, T., Konishi, F., Terada, M., and Wakasugi, H. Hemodydnamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancer xenograft. Cancer Res., 62: 560-566, 2002.
25. Kubota, Y., Kleinman, H., Martin, G. R., and Lawley, T. J. Role of laminin and basement membrane in the morphological differentiation of human endothelial cells into capillary-like structures. J. Cell. Biol., 107: 1589-1598, 1988.
26. Marconcini, L., Marchio, S., Morbidelli, L., Cartocci, E., Albini, A., Ziche, M., Bussilino, F., and Oliviero. S. c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro. Proc. Natl. Acad. Sci. USA, 96: 9671-9676, 1999.
27. Folkman, J., and Haudenschild, C. Angiogenesis in vitro. Nature (Lond.), 288: 551-556, 1980.
28. Dvorak, H. F., Nagy, J. A., Dvorak, J. T., and Dvorak, A. M. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am. J. Pathol., 133: 95-109, 1988.
29. James, S. E., and Salsbury, A. J. Effect of (plus or minus)-1,2-bis(3,5-dioxopiperazin-1-yl)propane on tumor blood vessels and its relationship to the antimetastatic effect in the Lewis lung carcinoma. Cancer Res., 34: 839-842, 1974.
30. Ellis, L. M., and Fidler, I. J. Angiogenesis and metastasis. Eur. J. Cancer, 32A: 2451-2460, 1996.
31. Hashizume, H., Baluk, P., Morikawa, S., McLean, J. W., Thurston, G., Robere, S., Jain, R. K., and McDonald, D. M. Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol., 156: 1363-1380, 2000.
32. Jain, R. K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med., 7: 987-989, 2001.
33. Braybrooke, J. P., O'Byrne, K. J., Propper, D. J., Blann, A., Saunders, M., Dobs, N., Han, C., Woodhull, J., Mitchell, K., Crew, J., Smith, K., Stephens, R., Ganesan, T. S., Talbot, D. C., and Harris, A. L. A Phase II study of Razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis. Clin. Can. Res., 6: 4697-4704, 2000.